ZLD1122, a novel EZH2 and EZH1 small molecular inhibitor, blocks H3K27 methylation and diffuse large B cell lymphoma cell growth
Tiantao Gao(Sichuan University), Luoting Yu(State Key Laboratory of Biotherapy), Weiqiong Zuo(Sichuan University), Ningyu Wang(Southwest Jiaotong University), Menghua Xiong(South China University of Technology), Xinyu You(State Key Laboratory of Biotherapy), Hongxia Deng(Sichuan University), Suxia Shi(Sichuan University), Li Liu(Bayer (United States)), Lidan Zhang(Sichuan University), Yongxia Zhu(University of Electronic Science and Technology of China), Xuejiao Song(Sichuan University), Cuiting Peng(Sichuan University), Qian Lei(Zhongnan Hospital of Wuhan University), Qiang Feng(École Polytechnique Fédérale de Lausanne), Yong Xia, Tinghong Ye(State Key Laboratory of Biotherapy)
Cited by 11
Related Papers
Global, regional, and national causes of child mortality: an updated systematic analysis for 2010 with time trends since 2000
|The Lancet|2012|4k
Global, regional, and national causes of under-5 mortality in 2000–15: an updated systematic analysis with implications for the Sustainable Development Goals
|The Lancet|2016|3.6k
Sorafenib Blocks the RAF/MEK/ERK Pathway, Inhibits Tumor Angiogenesis, and Induces Tumor Cell Apoptosis in Hepatocellular Carcinoma Model PLC/PRF/5
|Cancer Research|2006|1.5k
Anti–spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection
|JCI Insight|2019|914
Epidemiology of Carbapenem-Resistant Enterobacteriaceae Infections: Report from the China CRE Network
|Antimicrobial Agents and Chemotherapy|2017|461